Drug Profile


Alternative Names: BVF-025; JP-1730

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juvantia Pharma
  • Developer Juvantia Pharma; Santhera Pharmaceuticals
  • Class Antiparkinsonians; Imidazoles; Indans; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 19 Mar 2014 Fipamezole is available for licensing (
  • 24 Jan 2012 Fipamezole is no longer licensed to Ipsen worldwide
  • 18 Feb 2011 Fipamezole is no longer licensed to Biovail Laboratories in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top